CY1108457T1 - Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης - Google Patents
Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινηςInfo
- Publication number
- CY1108457T1 CY1108457T1 CY20081101212T CY081101212T CY1108457T1 CY 1108457 T1 CY1108457 T1 CY 1108457T1 CY 20081101212 T CY20081101212 T CY 20081101212T CY 081101212 T CY081101212 T CY 081101212T CY 1108457 T1 CY1108457 T1 CY 1108457T1
- Authority
- CY
- Cyprus
- Prior art keywords
- xanthinis
- adenosin
- competed
- receptor
- production
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
| EP03817096A EP1622908B1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108457T1 true CY1108457T1 (el) | 2014-04-09 |
Family
ID=33488737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101212T CY1108457T1 (el) | 2003-05-06 | 2008-10-27 | Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1622908B1 (enExample) |
| JP (1) | JP2006515316A (enExample) |
| CN (1) | CN100590125C (enExample) |
| AT (1) | ATE403656T1 (enExample) |
| AU (1) | AU2003249604B2 (enExample) |
| CA (1) | CA2524778C (enExample) |
| CY (1) | CY1108457T1 (enExample) |
| DE (1) | DE60322748D1 (enExample) |
| DK (1) | DK1622908T3 (enExample) |
| ES (1) | ES2311759T3 (enExample) |
| MX (1) | MXPA05011860A (enExample) |
| NZ (1) | NZ543416A (enExample) |
| PT (1) | PT1622908E (enExample) |
| SI (1) | SI1622908T1 (enExample) |
| WO (1) | WO2004106337A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2415858C2 (ru) * | 2005-06-16 | 2011-04-10 | Си Ви Терапьютикс, Инк. | Пролекарства антагонистов a2b рецептора аденозина |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| US20070208040A1 (en) * | 2006-03-02 | 2007-09-06 | Elfatih Elzein | A2a adenosine receptor antagonists |
| WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| BRPI0909157A2 (pt) * | 2008-03-26 | 2015-11-24 | Advinus Therapeutics Private Ltd | compostos heterocíclicos como antagonistas de receptores de adenosina |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| US8859566B2 (en) | 2009-03-13 | 2014-10-14 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| AU2011303420B2 (en) | 2010-09-13 | 2014-03-20 | Impetis Biosciences Ltd. | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
| EP2970303B3 (en) * | 2013-03-15 | 2018-08-01 | Hydra Biosciences, Inc. | Substituted xanthines and methods of use thereof |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
| US11045472B2 (en) * | 2017-05-05 | 2021-06-29 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| US20210040097A1 (en) * | 2018-03-05 | 2021-02-11 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| CN113727999A (zh) | 2019-01-11 | 2021-11-30 | 奥默罗斯公司 | 用于治疗癌症的方法和组合物 |
| CN118459463B (zh) * | 2024-07-10 | 2024-09-06 | 山东中医药大学附属医院 | 一种化合物及其制备方法和治疗2型糖尿病的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| US4878296A (en) * | 1988-04-22 | 1989-11-07 | The United States Of America As Represented By The Secretary Of The Navy | Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| ES2189079T3 (es) * | 1998-04-24 | 2003-07-01 | Leuven K U Res & Dev | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
| US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| KR100883292B1 (ko) * | 2001-06-29 | 2009-02-11 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체 |
| PT1444233E (pt) * | 2001-11-09 | 2011-09-29 | Gilead Palo Alto Inc | Antagonistas de receptor de adenosina a2b |
| WO2003063800A2 (en) * | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
-
2003
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en not_active Ceased
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 EP EP03817096A patent/EP1622908B1/en not_active Expired - Lifetime
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ543416A (en) | 2009-01-31 |
| EP1622908A1 (en) | 2006-02-08 |
| HK1092137A1 (en) | 2007-02-02 |
| DE60322748D1 (de) | 2008-09-18 |
| AU2003249604B2 (en) | 2011-06-30 |
| MXPA05011860A (es) | 2006-02-17 |
| JP2006515316A (ja) | 2006-05-25 |
| CN100590125C (zh) | 2010-02-17 |
| PT1622908E (pt) | 2008-11-14 |
| EP1622908B1 (en) | 2008-08-06 |
| ATE403656T1 (de) | 2008-08-15 |
| AU2003249604A1 (en) | 2005-01-21 |
| SI1622908T1 (sl) | 2008-12-31 |
| CN1771250A (zh) | 2006-05-10 |
| DK1622908T3 (da) | 2008-11-17 |
| ES2311759T3 (es) | 2009-02-16 |
| CA2524778A1 (en) | 2004-12-09 |
| WO2004106337A1 (en) | 2004-12-09 |
| CA2524778C (en) | 2013-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108457T1 (el) | Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης | |
| ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| SMAP200600024A (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia | |
| MY140010A (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
| CR7728A (es) | Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
| ATE438633T1 (de) | Benzo (d) isoxazol-3-yl-amin- verbindungen und deren verwendung als vanilloid-rezeptor liganden | |
| TNSN07272A1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists | |
| MXPA05013282A (es) | Derivados de pirimidina como ligandos del receptor de cannabinoides. | |
| NO20054078D0 (no) | Humane antistoffer spesifikke for Interleukin 15 (IL15). | |
| ATE541857T1 (de) | Optimierte fc-varianten und herstellungsverfahren dafür | |
| IL178365A (en) | Selective antagonists of a2a adenosine receptors | |
| CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
| ATE418555T1 (de) | A2a-adenosinrezeptorantagonisten | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| ATE435206T1 (de) | Heteroarylsulfonylstilbene als 5-ht2a- antagonisten | |
| DE60333866D1 (de) | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten | |
| NO20061952L (no) | Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
| TW200740814A (en) | Compounds | |
| EA200900010A1 (ru) | Замещенные 8-[6-амино-3-пиридил]ксантины | |
| EA201170563A1 (ru) | Метиленамины тиено[2,3-d]пиримидина и их применение в качестве антагонистов рецепторов a2a аденозина | |
| EP1600207A4 (en) | EMULSIFIER, METHOD FOR THE PRODUCTION THEREOF AND THE EMULSIFIED EMULSIFIED COMPOSITION | |
| EA200500005A1 (ru) | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина | |
| UY29440A1 (es) | Nuevos compuestos |